OTCPK:FRLI

Stock Analysis Report

Executive Summary

Frélii, Inc. provides personalized subscription based nutrition and wellness programs.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Share Price & News

How has Frélii 's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

FRLI

1.4%

US Healthcare Services

1.8%

US Market


1 Year Return

-94.4%

FRLI

15.6%

US Healthcare Services

7.3%

US Market

Return vs Industry: FRLI underperformed the US Healthcare Services industry which returned 15.6% over the past year.

Return vs Market: FRLI underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

FRLIIndustryMarket
7 Day0%1.4%1.8%
30 Day-35.5%-0.9%-0.7%
90 Day-78.7%-5.3%0.06%
1 Year-94.4%-94.4%15.8%15.6%9.7%7.3%
3 Yearn/a57.1%56.6%46.3%36.9%
5 Year-90.0%-90.0%49.8%48.7%64.5%46.5%

Price Volatility Vs. Market

How volatile is Frélii 's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Frélii undervalued compared to its fair value and its price relative to the market?

2.64x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate FRLI's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate FRLI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FRLI is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: FRLI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate FRLI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FRLI is good value based on its PB Ratio (2.6x) compared to the US Healthcare Services industry average (3.7x).


Next Steps

Future Growth

How is Frélii forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Frélii has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of FRLI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Frélii 's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Frélii performed over the past 5 years?

-64.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: FRLI is unprofitable, and losses have increased over the past 5 years at a rate of -64.6% per year.

Accelerating Growth: Unable to compare FRLI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FRLI is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.3%).


Return on Equity

High ROE: FRLI has a negative Return on Equity (-273.49%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: FRLI is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: FRLI is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Frélii 's financial position?


Financial Position Analysis

Short Term Liabilities: FRLI's short term assets ($175.3K) do not cover its short term liabilities ($236.5K)

Long Term Liabilities: FRLI has no long term liabilities


Debt to Equity History and Analysis

Debt Level: FRLI is debt free.

Reducing Debt: FRLI currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: FRLI has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if FRLI's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FRLI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: FRLI has less than a year of cash runway if free cash flow continues to reduce at historical rates of -117.5% each year


Next Steps

Dividend

What is Frélii 's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate FRLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate FRLI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if FRLI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FRLI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FRLI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Frélii 's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Ian Jenkins (35yo)

2.5yrs

Tenure

US$286,375

Compensation

Mr. Ian Geran Jenkins has been the Chief Executive Officer and Chief Financial Officer of Frélii, Inc. (formerly known as Vican Resources, Inc.) since April 5, 2017 and serve as President. Mr. Jenkins has  ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Ian's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Ian's compensation with company performance.


Management Age and Tenure

1.5yrs

Average Tenure

38.5yo

Average Age

Experienced Management: FRLI's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Age and Tenure

1.1yrs

Average Tenure

44yo

Average Age

Experienced Board: FRLI's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Ian Jenkins (35yo)

    President

    • Tenure: 2.5yrs
    • Compensation: US$286.38k
  • Seth Jones (30yo)

    Chief Marketing Officer

    • Tenure: 1.8yrs
    • Compensation: US$97.81k
  • Hans Jenkins (42yo)

    Chief Medical Officer & Director

    • Tenure: 1.6yrs
  • Jayson Uffens (44yo)

    CTO & Director

    • Tenure: 0yrs
  • Sandeep Uppal

    Chief Administrative Officer

    • Tenure: 0.4yrs
  • Yvan Aubin

    Executive VP of Finance

    • Tenure: 0.4yrs

Board Members

  • Anthony Torres

    Member of Scientific Advisory Committee

    • Tenure: 0.7yrs
  • Ian Jenkins (35yo)

    President

    • Tenure: 2.5yrs
    • Compensation: US$286.38k
  • Hans Jenkins (42yo)

    Chief Medical Officer & Director

    • Tenure: 1.6yrs
  • Jim Spallino (60yo)

    Chairman of the Board

    • Tenure: 0yrs
  • Tarek Mango (49yo)

    Director

    • Tenure: 1.8yrs
  • Susan Morelli

    Member of Scientific Advisory Committee

    • Tenure: 0.7yrs
  • Shayne Morris

    Member of Scientific Advisory Committee

    • Tenure: 0.7yrs
  • Jayson Uffens (44yo)

    CTO & Director

    • Tenure: 0yrs
  • Shannon Jenkins

    Member of Scientific Advisory Committee

    • Tenure: 0yrs

Company Information

Frélii, Inc. 's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Frélii, Inc.
  • Ticker: FRLI
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$5.340m
  • Shares outstanding: 53.40m
  • Website: https://www.frelii.com

Number of Employees


Location

  • Frélii, Inc.
  • 2701 North Thanksgiving Way
  • Suite 100
  • Lehi
  • Utah
  • 84043
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FRLIOTCPK (Pink Sheets LLC)YesClass A Common StockUSUSDAug 2009

Biography

Frélii, Inc. provides personalized subscription based nutrition and wellness programs. The company offers health assessments and nutrition plans based on genetic data, physiology, environmental and lifesty ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:14
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.